Drug Interactions and Adverse Events in a Cohort of Warfarin Users Attending Public
            Health Clinics

Colet, Christiane de Fátima; Amador, Tânia Alves; Heineck, Isabela

doi:10.5935/2359-4802.20180091

Cited by 4 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the available literature evidence, it is safe to introduce this therapy after 48 hours of the admission in patients with stable hematoma who have a more severe clinical picture and a high risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) (Dastur, Yu, 2017). Anticoagulant therapy has a significant role in pDDIs (Tesfaye, Nedi 2017;Colet, Amador, Heineck, 2019), especially when it comes to clinically relevant drug interactions (Vazquez, 2018). For example, warfarin is recognized as a drug that has numerous interactions and 99.2% of hospitalized patients who were prescribed this anticoagulant, were exposed to pDDI, 16% of whom experienced gastrointestinal bleeding as a complication (Teklay et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Potential drug-drug interactions among patients with spontaneous intracerebral hemorrhage treated at the Neurological Intensive Care Unit: a single-center experience

Aleksić

Milosavljević

Janković

et al. 2022

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Our aim was to determine the prevalence of potential drug-drug interactions (pDDIs) and to identify relevant factors associated with the occurrence of the most dangerous or contraindicated pDDIs (pCDDIs) in hospitalized patients with spontaneous intracerebral hemorrhage (sICH). A retrospective cross-sectional study was performed enrolling all consecutive patients with sICH treated at the Neurological Intensive Care Unit, Clinical Center in Kragujevac, Serbia, during the three-year period (2012)(2013)(2014). The inclusion criteria encompassed patients aged 18 years and over, those diagnosed with ICH, and those prescribed at least two drugs during hospitalization, while we did not include patients whose hospitalization lasted less than 7 days, those who were diagnosed with other neurological diseases and patients with incomplete medical files. For each day of hospitalization, the online checker Micromedex® software was used to identify pDDIs and classify them according to severity. A total of 110 participants were analysed. A high prevalence of pDDIs (98.2%) was observed. The median number of pDDIs regardless of severity, was 8.00 . The pairs of drugs involving cardiovascular medicines were the most commonly identified pDDIs. Twenty percent of the total number of participants was exposed to pCDDIs. The use of multiple drugs from different pharmacological-chemical subgroups and the prescribing of anticoagulant therapy significantly increase the chance of pCDDI (aOR with 95% CI 1. 19 (1.05-1.35) and 7.40 (1.13-48.96), respectively). This study indicates a high prevalence of pDDIs and pCDDIs in patients with sICH. The use of anticoagulant therapy appears to be the only modifiable clinically relevant predictor of pCDDIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential drug-drug interactions among patients with spontaneous intracerebral hemorrhage treated at the Neurological Intensive Care Unit: a single-center experience

Aleksić

Milosavljević

Janković

et al. 2022

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…(27,28) O conhecimento multidisciplinar é uma ferramenta fundamental no ensino em saúde e contribui para o alcance do sucesso no tratamento com ACO, nessa perspectiva, deve--se levar em conta o planejamento da assistência, levando em consideração todos os aspectos da terapia e, o contexto que está inserida a população alvo com seus fatores individuais e coletivos. (29) Como limitação do estudo aponta-se a diminuição no tamanho da amostra, motivada pelo fato de durante o período…”

Section: Discussionunclassified

Avaliação Do Conhecimento Sobre a Terapêutica Medicamentosa De Indivíduos Em Uso De Anticoagulantes Orais

Silva¹,

Silveira²,

Silva³

et al. 2022

Enfermagem Em Foco

View full text Add to dashboard Cite

Objetivo: Avaliar o conhecimento sobre a terapêutica medicamentosa de indivíduos em uso de anticoagulantes orais. Métodos: Estudo transversal, quantitativo, com participação de 90 indivíduos em uso de anticoagulantes orais acompanhados em ambulatório de anticoagulação em Recife-PE. Os dados foram coletados de abril a julho de 2020 através de dois questionários, analisados por estatística descritiva e dispostos em tabelas. Resultados: A maioria dos indivíduos (42,2%) apresentou conhecimento adequado acerca do tratamento. Na associação do conhecimento com outras variáveis, houve significância estatística entre conhecimento adequado com resultados do International Normalized Ratio dentro da faixa indicada (p=0,001) e com idade menor que 60 anos (p=0,018), e entre conhecimento inadequado com baixa escolaridade (p=0,045), hipertensão (p=0,009) e tabagismo (p=0,041). Conclusão: A maioria dos indivíduos apresentou conhecimento adequado acerca do tratamento. Houve associação significativa entre conhecimento adequado e resultados do INR e entre a idade, assim como conhecimento inadequado e baixa escolaridade, não ser tabagista e hipertensão.

show abstract

“…The data used for this analysis are part of a prospective open cohort that includes warfarin users linked to the public health network in the municipality of Ijuí, RS, Brazil, which has a population of 79,396 inhabitants. Data related to drug interactions and adverse events 5 have been published and data on patients’ therapeutic itineraries have also been published. 6 …”

Section: Methodsmentioning

confidence: 99%

Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Genetic factors can be responsible for part of the populational and interindividual differences observed in warfarin users. Objectives To identify occurrence of polymorphisms of the CYP2C9 and VKORC1 genes in patients taking warfarin and relate these profiles to their medication dosages and the Time in Therapeutic Range (TTR). Methods Monthly interviews were conducted for data collection. Data were collected on demographic characteristics and medications in use, especially warfarin, including reason for prescription and weekly dose. TTR was calculated as the percentage of days with international normalized ratio (INR) between 2 and 3. The CYP2C9 and VKORC1 genes were analyzed at a Human Genetics Laboratory. Results 49 patients (74.2%) had polymorphisms of the CYP2C9 and/or VKORC1 genes; the remaining 17 (25.8%) did not have these polymorphisms. The average weekly dose of warfarin was lower among those who had a polymorphism for any of the genes compared to those who did not, with a significant difference (p = 0.035). The mean TTR was also lower among patients with polymorphism. However, the difference between the two groups was not significant for this variable (p = 0.438). Conclusions An association was observed between the polymorphisms and the warfarin doses taken by the patients. However, there was no association with adverse events or the time spent within the therapeutic range in this sample.

show abstract

Drug Interactions and Adverse Events in a Cohort of Warfarin Users Attending Public Health Clinics

Cited by 4 publications

References 1 publication

Potential drug-drug interactions among patients with spontaneous intracerebral hemorrhage treated at the Neurological Intensive Care Unit: a single-center experience

Potential drug-drug interactions among patients with spontaneous intracerebral hemorrhage treated at the Neurological Intensive Care Unit: a single-center experience

Avaliação Do Conhecimento Sobre a Terapêutica Medicamentosa De Indivíduos Em Uso De Anticoagulantes Orais

Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil

Contact Info

Product

Resources

About